Ongoing and Novel Challenges in Kidney Transplantation: Therapeutic Approaches to Non-Immunological Risk Factors for Allograft Loss

Read full text
Authors: Michele Provenzano, Roberta Arena, Ida Gagliardi, Lilio Hu, Chiara Ruotolo, Gemma Patella, Giuseppe Pezzi, Rosita Greco, Valeria Grandinetti, Rocco Malivindi, Michele Di Dio, Olga Baraldi
+2 more Giorgia Comai, Luca De Nicola
Cited by: 1
References: 182

Abstract

In recent decades, the rate of kidney transplantation has risen significantly, leading to better outcomes in terms of cardiovascular and overall mortality for patients with kidney failure. Although kidney transplantation represents the most effective therapeutic option, it is not devoid of the risk of failure. Immunological and non-immunological risk factors are involved. These factors often interact and may act synergistically, ultimately influencing graft longevity and patient survival. Both contribute to long-term transplant outcomes; however, non-immunological factors, representing a significant clinical challenge, will be the focus of our review. Of the numerous non-immunological risk factors, for clarity and to avoid overextending the discussion, only those most closely associated with chronic kidney disease have been considered: hypertension, anemia, diabetes mellitus, proteinuria, electrolyte and acid-base imbalances, and impaired bone mineralization. Hypertension is reported in approximately 90% of kidney transplant recipients, often related to immunosuppressive therapy and residual renal dysfunction, and it is strongly associated with reduced graft survival. Anemia affects approximately 20-51% of these patients, contributing to cardiovascular morbidity and a more rapid decline in graft function, as does pre-existing diabetes mellitus. Proteinuria has a prevalence ranging from 7.5% to 45%, depending on the established target, and is a significant negative prognostic factor. Metabolic complications are also frequent; for example, hyperkalemia has an incidence of 25-44%, and metabolic acidosis has a prevalence of 12-58%. In our review, each of these factors is analyzed in terms of clinical impact, etiopathogenic mechanism, and available therapeutic management.

Fields of Study & Subjects

Renal Transplantation Outcomes and Treatments Potassium and Related Disorders Erythropoietin and Anemia Treatment

Publication details

Journal / source
Life
Publisher
MDPI AG
Volume
16
Issue
2
Pages
248–248
Publication date
2 February 2026
Language
EN